| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
We previously reported the synergic effect of photodynamic therapy and dendritic cell cancer vaccine therapy for mouse cancer models(Saji H et al, Clin Cancer Res. 2006). In this program, we performed the preclinical research for the possible clinical application of minimum invasive anti-cancer therapy in combination with dendritic cell cancer vaccine.
It must be very essential to recognize the exact host immune-status against cancer for development of cancer immunotherapy. Expression of the transcription factor FOXP3 characterizes regulatory T cells that engage in the maintenance of immunological self-tolerance and immune homeostasis. First we analyzed the expression of FOXP3 positive lymphocytes in 50 non-small cell lung cancer(NSCLC) tissues and assessed the correlation between these expression and clinicopathological factors. There is no correlation between these expression and age or gender. Expression of FOXP3 positive lymphocytes were increased in adenocarcinoma compared with non-adenocarcinoma. There was positive correlation between these expression and lymph node metastasis. Therefore, we further study this analysis in additional 100 NSCLC tissues. Secondary, we have conducted the clinical cancer vaccine trial of intratumoral dendritic cell injection in combination with photodynamic therapy, radiofrequency ablation or chemotherapy for locally advanced non resectable NSCLC.
|
